

Published in final edited form as:


Org Lett. 2008 November 6; 10(21): 4955–4957. doi:10.1021/ol802041c.

A Concise and Modular Synthesis of Pyranicin

Nolan D. Griggs and Andrew J. Phillips*

Department of Chemistry and Biochemistry, University of Colorado at Boulder, Boulder, CO 80309-0215

Abstract



A modular, 13 step, synthesis of the tetrahydropyran-containing annonaceous acetogenin pyranicin is reported. Key features are the use of an Achmatowicz oxidation-Kishi reduction sequence for the assembly of a pyranone from a furan, and the application of Fu's alkyl-alkyl Suzuki coupling for subunit union.

The annonaceous acetogenins, a group of polyketides that are generally identified by the presence of one or two tetrahydrofuran rings, now number greater than 400 compounds.¹ A small subset of the acetogenins, including mucocin and jimenezin, contain both a tetrahydrofuran ring and a tetrahydropyran ring. As a class, these compounds have attracted substantial scientific attention due to their rich and varied biological activities which include anticancer, antiinfective, immunosuppressive, pesticidal, and antifeedant properties.

Pyranicin (**1**, Figure 1) was isolated from the stem bark of *Goniothalamus giganteus* Hook. f. & Thomas (Annonaceae) and is the prototype of acetogenins that contain a single tetrahydropyran ring.² Despite what could be argued to be substantial structural simplification relative to more complex acetogenins, pyranicin retains impressive biological activity, with <1 μg/mL ED₅₀ values against a number of cancer cell lines and particularly noteworthy effects against the PACA-2 (pancreatic cancer) cell line (ED₅₀ = 1.3 ng/mL). As part of our ongoing interest in the synthesis of natural product inhibitors of electron transport,³ we describe in this communication a total synthesis of **1**.⁴

From the outset, an overarching goal of our studies was to develop a concise and modular synthesis that would be amenable to the synthesis of a variety of compounds that could illuminate SAR for pyranicin. With this in mind, we settled on a strategy that called for the preparation of three key subunits: pyran **2**, alkynyl olefin **3**, and butenolide **4**. Pyran **2** would be prepared by our recently described Achmatowicz oxidation-Kishi reduction sequence,⁵ and our plans for subunit coupling involved the use of Carreira's asymmetric alkynylation⁶ and Fu's recently described alkyl-alkyl Suzuki coupling.⁷

The synthesis of the tetrahydropyran-containing domain commenced with commercially available furan **5**⁸ (Scheme 1). Addition of dodecylmagnesium bromide produced furfuryl

andrew.phillips@colorado.edu.

 Supporting Information Available: Procedures for the synthesis of new compounds, along with characterization data, and spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

alcohol **6**, which was subjected to the Sharpless asymmetric kinetic resolution reported by Sato^{9,10} to yield the intermediate pyranone hemiacetal **7**. Immediate reduction with *i*-Pr₃SiH in the presence of BF₃·OEt₂ gave pyran **8** as a single diastereoisomer (>20:1 by ¹H NMR analysis). This three step sequence conveniently provided the desired pyran in 33% overall yield. Hydrogenation of the enone, followed by reduction of the ketone with L-Selectride gave axial alcohol **9** in 86% yield (2 steps). Protection of the secondary alcohol as the TBS ether, removal of the benzyl ether (88% yield, 2 steps), and oxidation with Dess-Martin periodinane led to aldehyde **2** (99% yield). Reaction with known alkyne **3**¹¹ under Carreira's asymmetric alkynylation conditions (Et₃N, Zn(OTf)₂, (-)-NME, PhMe) and subsequent protection of the secondary alcohol as the TBS ether gave **10** (82% yield over 2 steps).

The synthesis of butenolide **4** began with the alkylation of alkyne **11**¹² with epoxide **12**¹³ in the presence of BF₃·OEt₂, followed by immediate protection of the homopropargyl alcohol with TBDSPCl to give **13** in 88% yield (Scheme 2). Careful removal of the TBS ether with ethanolic PPTS (95% yield) and hydroalumination-iodination of the alkyne following Denmark's procedure¹⁴ produced vinyl iodide **14** in 90% yield. In accord with Stille's original report¹⁵ and Hoye's application in the context of acetogenin synthesis,¹⁶ when **14** was subjected to Pd(0) under 50 psi CO, carbonylative lactonization occurred to yield the desired butenolide **15** in 90% yield. Oxidative removal of the PMB ether with DDQ in wet CH₂Cl₂ (82% yield) unveiled primary alcohol **16**. Conversion of the alcohol to the bromide **4** was readily achieved by Hannesian's NBS-Ph₃P protocol¹⁷ in 87% yield.

With routes to **10** and **4** secured we were positioned to examine the proposed Fu-type Suzuki coupling for subunit union (Scheme 2).¹⁸ To this end, when **10** was treated with 1.1 equivalents of freshly prepared 9-BBN in THF at room temperature, hydroboration was selective for the terminal alkene over the internal alkyne¹⁹ to yield intermediate borane **17**. When this borane was exposed to bromide **4**, Pd(PCy₃)₂ and K₃PO₄·H₂O smooth cross-coupling ensued to yield the desired compound **18** in 60% yield. In our hands, this coupling was robust with 20 mol% Pd(PCy₃)₂ catalyst loading and 1.2 equivalents of bromide **4**. In the current example, deviation from these conditions resulted in decreased and variable yields of the desired compound. The synthesis was then completed in a straightforward fashion by removal of the silyl protecting groups with aqueous HF in acetonitrile (92% yield), and reduction of the alkyne to the hydrocarbon using Wilkinson's catalyst in benzene-ethanol to produce pyranicin, **1** in 89% yield. The physical characteristics of synthetic material (¹H and ¹³C NMR, HRMS) matched those reported by McLaughlin.² Optical rotation data was in accord with that reported by Rein and Takahashi.^{20,21}

In conclusion, we have described a concise (13 steps longest linear sequence) and efficient (10% overall yield) synthesis of pyranicin. Beyond these metrics, the synthesis is modular and will prove amenable to the synthesis of a variety of analogs. This work also highlights the utility of the Achmatowicz oxidation-Kishi reduction sequence for the assembly of pyrans and the strategic potential of alkyl-alkyl Suzuki couplings in a complex setting.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Eli Lilly and Company (via the Lilly Grantee Program), the AP Sloan Foundation, and the National Cancer Institute (CA 110246) for support of this research.

References

1. For a review see: Bermejo A, Figadere B, Zafra-Polo M-C, Barrachina I, Estornell E, Cortes D. *Nat Prod Rep* 2005;22:269. [PubMed: 15806200] and references cited therein.
2. Alali FQ, Rogers L, Zhang Y, McLaughlin JL. *Tetrahedron* 1998;54:5833.
3. Keaton KA, Phillips AJ. *J Am Chem Soc* 2006;128:408. [PubMed: 16402817]
4. For other total syntheses see: (a) Strand D, Norrby PO, Rein T. *J Org Chem* 2006;71:1879. [PubMed: 16496972] (b) Strand D, Rein T. *Org Lett* 2005;7:199. [PubMed: 15646957] (c) Takahashi S, Kubota A, Nakata T. *Org Lett* 2003;5:1353. [PubMed: 12688757] (d) Hattori Y, Furuhashi S-i, Okajima M, Konno H, Abe M, Miyoshi H, Goto T, Makabe H. *Org Lett* 2008;10:717. [PubMed: 18251547] (e) Furuhashi S-i; Hattori, Y.; Okajima, M.; Konno, H.; Abe, M.; Miyoshi, H.; Goto, T.; Makabe, H. *Tetrahedron* 2008;64:7695.
5. (a) Henderson JA, Jackson KL, Phillips AJ. *Org Lett* 2007;9:5299. [PubMed: 17999514] (b) Um JM, Houk KN, Phillips AJ. *Org Lett* 2008;10:3769. [PubMed: 18646767] See also (c) Nicolaou KC, Frederick MO, Burtoloso ACB, Denton RM, Rivas F, Cole KP, Aversa RJ, Gibe R, Umezawa T, Suzuki TJ. *Am Chem Soc* 2008;130:7466.
6. Anand NK, Carreira EM. *J Am Chem Soc* 2001;123:9687. [PubMed: 11572696]
7. Netherton MR, Dai C, Neuschutz K, Fu GC. *J Am Chem Soc* 2001;123:10099. [PubMed: 11592890]
8. This furan is also readily prepared by benzylation of (hydroxymethyl) furfural. See Cottier L, Descotes G, Eymard L, Rapp K. *Synthesis* 1995:303.
9. Kobayashi Y, Kusakabe M, Kitano Y, Sato F. *J Org Chem* 1988;53:1586.
10. For the CaH₂/SiO₂ modified conditions employed here see: (a) Yang ZC, Zhou WS. *Tetrahedron Lett* 1995;36:5617. (b) Zhou WS, Lu Z, Wang Z. *Tetrahedron Lett* 1991;32:1467. (c) Wang Z, Zhou W, Lin G. *Tetrahedron Lett* 1985;26:6221.
11. Garcia-Fandino R, Aldegunde MJ, Codesido EM, Castedo L, Granja JR. *J Org Chem* 2005;70:8281. [PubMed: 16209568]
12. Brimble MA, Bryant CJ. *Org Biomol Chem* 2007;5:2858. [PubMed: 17700855]
13. Marshall JA, Schaaf G, Nolting A. *Org Lett* 2005;7:5331. [PubMed: 16268571]
14. (a) Chan K, Cohen N, DeNoble JP, Specian AC, Saucy G. *J Org Chem* 1976;41:3497. [PubMed: 978300] (b) Denmark SE, Jones TK. *J Org Chem* 1982;47:4595.
15. Cowell A, Stille JK. *J Am Chem Soc* 1980;102:4193.
16. Hoye TR, Humpal PE, Jimenez JI, Mayer MJ, Tan L, Ye Z. *Tetrahedron Lett* 1994;35:7517.
17. Ponpipom MM, Hanessian S. *Carbohydr Res* 1971;18:342.
18. For other examples of the use of this reaction in total synthesis see: (a) Das S, Abraham S, Sinha SC. *Org Lett* 2007;9:2273. [PubMed: 17503834] (b) Keaton KA, Phillips AJ. *Org Lett* 2007;9:2717. [PubMed: 17559220]
19. Brown CA, Coleman RA. *J Org Chem* 1979;44:2328.
20. As described and discussed by Rein and Takahashi in references 4a, 4b and 4c, there is a discrepancy between the optical rotations for synthetic and natural pyranicin: natural pyranicin [α]_D -9.7 (c 0.008, CHCl₃); synthetic pyranicin (Takahashi): [α]_D +19.5 (c 0.55, CHCl₃); synthetic pyranicin (Rein): [α]_D +21.1 (c 0.24, CHCl₃). Our material had optical rotation of [α]_D +24.8 (c 0.20, CHCl₃).
21. The possibility of the discrepancy in optical rotations being due to aggregation effects was seems unlikely as the rotation in chloroform for our synthetic material does not vary significantly with changing concentration:

Concentration (c)	α [α] _D
0.200	+0.0424.8
0.125	+0.02217.8
0.063	+0.0126.3
0.031	+0.0072.7

<u>Concentration (c) α [σ]_p</u>	
0.015	+0.0021.3






Figure 1.
Pyranicin and overall synthesis strategy.



Scheme 1.
Synthesis of the C7–C32 pyran-containing domain.

**Scheme 2.**

Synthesis of the butenolide domain and completion of the synthesis.